Clinical Trial Update: Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting safety and efficacy results for ERB-041 in reducing endometriosis-related symptoms in reproductive-aged women.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometriosis

Drugs mentioned

• ERB-041

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Dysmenorrhea, Dyspareunia | Phase 2 | Status: COMPLETED